Having completed the acquisition of Avedro, Glaukos is expanding its business focus beyond glaucoma to deliver treatments for other chronic eye conditions such as corneal disorders and retinal diseases.
As of 1 January 2020, the global company that is well known in Australia for the iStent Inject W trabecular micro-bypass, is responsible for direct sales and marketing of Avedro products under the brand name iLink V.
iLink V corneal cross-linking technology comprises proprietary VibeX Rapid riboflavin and the ultraviolet A light from the KXL System used for the treatment of progressive keratoconus.
The therapy is the first and only United States Food and Drug Administration-approved therapeutic treatment for patients with progressive keratoconus and corneal ectasia following refractive surgery. Over 400,000 crosslinking procedures have been performed globally using the technology.
Thomas Burns, Glaukos president and chief executive officer, has said that Avedro is the cornerstone of Glaucoma’s new corneal health franchise. Speaking at the time of the company’s acquisition in November 2019, he said Glaukos and Avedro are “two highly complementary, hybrid pharma and device organisations, combining Avedro’s novel bio-activated pharmaceutical solutions and R&D capabilities with Glaukos’ global commercial scale, proven market-building and shared reimbursement expertise, and extensive clinical and regulatory infrastructure”.
